The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period.
A rising elderly population, an increasing number of patients with liver disease, a big smoking population, an expanding number of patients with diabetes, and improved safety and efficacy of present and new medicines, among other factors, are driving the Cholangiocarcinoma Market. Furthermore, the introduction of technologically advanced diagnostics that aid in tumour progression monitoring, assessing therapeutic response and clinical prognosis, and detecting recurrent tumours is contributing to the market’s positive outlook.
Cholangiocarcinoma is a kind of cancer that occurs when epithelial cells in the bile ducts become mutated. Prolonged inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection caused by the liver flukes parasite, and exposure to toxic chemicals and poisons are all major causes of disease development. It mainly affects persons over the age of 65, but it can happen at any age. Men are slightly more likely than women to develop cholangiocarcinoma. Typically, the indication does not cause symptoms until it has progressed to an advanced stage and has spread to other organs and tissues. However, only a few patients may experience early symptoms.
Click Here, Download a Free Sample Copy of this Market: https://wemarketresearch.com/sample-request/cholangiocarcinoma-market/897/
Key Companies Insights
The market for cholangiocarcinoma is moderately competitive. With the rising applications of Cholangiocarcinoma, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Cholangiocarcinoma market, ultimately boosting the market growth. Some of the key companies working in the global Cholangiocarcinoma market include:
• Johnson & Johnson Private Limited
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• AstraZeneca
• GlaxoSmithKline plc
• AbbVie Inc.
• Novartis AG
• Fresenius Kabi AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Intercept Pharmaceuticals
• Kyowa Kirin Co., Ltd.
• Delcath Systems, Inc.
• Accord Healthcare
• CONMED Corporation
• Boston Scientific Corporation
• Bayer AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Other players
Some of the Recent Developments:
• In April 2020, the U.S. Food and Drug Administration had permitted the first targeted therapy for patients with cholangiocarcinoma called Pemazyre (pemigatinib). Pemazyre’s sanction was founded on the outcomes of a clinical trial in which 107 patients with locally progressive or metastatic cholangiocarcinoma who had earlier received therapy and had a FGFR2 fusion or rearrangement were joined.
• In September 2019, Merck Sharp & Dohme Corp initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment bile duct cancer. The study is now in Phase 3 clinical trials and is anticipated to be completed by August 2023.
Segments
By Treatment Type
• Chemotherapy
o Gemcitabine
o Cisplatin
o Oxaliplatin
o Oxaliplatin
o 5 fluorouracil (5-FU)
• Targeted Therapy
o Pemigatinib
o Infigratinib (Phase 3)
o Ivosidenib (Phase 3)
• Immunotherapy
o Pembrolizumab (Phase 3)
• Others
By Disease Indication
• Intrahepatic Bile Duct Cancer
• Extrahepatic Bile Duct Cancer
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
Region Insights:
North America is governing the market, and it is anticipated that it will remain to dominate in the forecasted period. The factors the region embraces the major growth are the well-developed healthcare sector, growing number of cancer patients, and accumulating government expenditure on healthcare. In 2015, healthcare expenditure in the U.S. touched $3.2 trillion per person, 17.8% of the total GDP. The accessibility of funds for research, intensifying patient population and government support for the research and development of medication in Europe and Asia pushes the market towards growth.
Europe holds the second-largest cholangiocarcinoma market share. Owing to the continuous growth in the region like India and China, the market is experiencing high opportunities in the future. In India, the healthcare spending accounted for the fastest CAGR.
Purchase Cholangiocarcinoma Market Report: https://wemarketresearch.com/purchase/cholangiocarcinoma-market/897/?license=single
The worldwide healthcare industry is predicted to expand further, owing to reasons such as an ageing population, the rise of chronic diseases, and rising healthcare spending in emerging markets. Pharmaceutical and biotech businesses, medical device makers, and healthcare providers such as hospitals and clinics are among the industry’s key players. The industry is also seeing an increase in interest in digital health solutions, such as telemedicine and health-related smartphone apps, which are gaining popularity among both patients and healthcare professionals. Overall, the healthcare business is a dynamic and continuously changing sector that plays an important part in our society and will continue to be a major emphasis in the coming years.
The healthcare industry is enormous and ever-changing, encompassing a diverse range of products and services. The healthcare market is continually developing and evolving, from drugs and medical devices to healthcare IT and telemedicine. As the population ages and the prevalence of chronic diseases rises, so does the need for healthcare services and products. The COVID-19 pandemic has also resulted in considerable changes in the healthcare industry, with a greater emphasis on remote care and digital health solutions. As a result, the healthcare business is predicted to grow rapidly in the future years, with new technologies and advancements propelling the market forward.
Get A Report Copy of this Market: https://wemarketresearch.com/reports/cholangiocarcinoma-market/897/
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
1. What are the current marketed Cholangiocarcinoma drugs and what are their market performance?
2. What are the key pipeline Cholangiocarcinoma drugs and how are they expected to perform in the coming years?
3. How safe are the current marketed Cholangiocarcinoma drugs and what are their efficacies?
4. How safe are the late-stage pipeline Cholangiocarcinoma drugs and what are their efficacies?
5. What are the current treatment guidelines for Cholangiocarcinoma drugs across the seven major markets?
6. Who are the key companies in the Cholangiocarcinoma market and what are their market shares?
7. What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Cholangiocarcinoma market?
Contact Us:
We Market Research
Phone: +1(650)-666-4592
Email: [email protected]
Web: https://wemarketresearch.com/
About We Market Research:
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
